NASDAQ · PTN
Palatin Technologies, Inc.
Healthcare · Biotechnology
$8.30▲ 1.34% ($0.11)today
As of 9:31 AM ET
Market cap
$14.77M
P/E
N/M
EPS (TTM)
-$2.14
Next earnings
Nov 16, 2026
Valuation
Revenue & margin DCF
Verdict: cheap. Price below all scenarios.
The price needs 5.0% revenue growth a year for 10 years. Our scenarios assume 14.1–24.4%.
That's below its past 4-year pace of 73.1%.
Value per share
Base case
$38.90
Price used $8.30 is 79% below this
USD · TTM ending Jun 30, 2026 · Price Oct 14, 1:31 PM UTC
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span.
1 more note
This estimate is at least 3× the price used. Review the growth, margin and investment assumptions behind the gap.
Revenue each value needs
Revenue today $13.2M. The price needs $21.5M by 2036. Base case: $79.1M. At its recent pace: $3.2B. Bear to Bull: $49.1M to $117M.
Revenue today $13.2M. The price needs $21.5M by 2036. Base case: $79.1M. At its recent pace: $3.2B. Bear to Bull: $49.1M to $117M.
Revenue in 2036
today $13.2M
−$57.6Mless than the Base case
Value per share · Base case
$38.90
Price $8.30
79% below this
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 0.0%
- Discount rate
- 7.4%
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span.
1 more note
This estimate is at least 3× the price used. Review the growth, margin and investment assumptions behind the gap.
USD · TTM ending Jun 30, 2026 · Price Oct 14, 1:31 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 12.97% over the last year. Free cash flow grew 36.24% in FY2026 versus FY2025.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum. The operating data is doing enough work that the move does not need an overvaluation story to explain it.
What would invalidate this read
Operating margin is at -65.74%. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Return analysis
Company profile
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
Market multiples
Stock splits
Every 50 shares became 1
Every 25 shares became 1
Every 10 shares became 1
Every 4 shares became 1
Every 10 shares became 1
Profitability & growth
Analyst consensus
3
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 16, 2026
Q1 FY27 · EPS est -$0.42 · Revenue est $2.5M
Q4 FY26
Reported Sep 28, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$1.11
Estimate
-$1.20
Year over year
n/m
Vs prior quarter
n/m
2 beats · 1 miss in 3 of the last 4 quarters
Institutional Sentiment
Palatin Technologies, Inc. · PTN
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.